Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Year 2 Collaborative Project - UCSF and Battelle PNWD

Year 2 Collaborative Project - UCSF and Battelle PNWD

238
amphiregulin, CA15-3, CD14, epidermal growth factor (EGF), EGF receptor, E-selectin, basic fibroblast growth factor, heparin-binding EGF, Her2, hepatocyte growth factor, intracellular adhesion molecule, insulin-like growth factor 1, interleukins 1 and 18, matrix metalloproteases 1, 2 and 9, platelet-derived growth factor, prostate-selective antigen, RANTES, transforming growth factor , tissue necrosis factor , urokinase plasminogen activator, vascular endothelial growth factor
Proteomics
Breast and Gynecologic Cancers Research

To evaluate the effects of receptor status on circulating biomarker levels.

To analyze plasma levels of 24 proteins in 60 samples from women with either benign breast disease, or Her+ or ER+ cancers.
ELISA microarray

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 03/14/2018
Thank you to everyone to made the 10th EDRN Scientific Workshop a success. The next event is the 33rd EDRN Steering Committee Meeting from September 5-6, 2018 in Boston, MA. Details will be available soon.


Three new FOAs on the Human Tumor Atlas and associated with the Cancer Moonshot Initiative have been released. Please click here for more information.

Announcement 10/23/2017

Three new FOAs on the Human Tumor Atlas and associated with the Cancer Moonshot Initiative have been released. Please click here for more information.

EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.